Athenex Inc (NASDAQ:ATNX) Director Jinn Wu acquired 10,000 shares of the firm’s stock in a transaction dated Monday, March 26th. The shares were purchased at an average price of $14.66 per share, for a total transaction of $146,600.00. Following the completion of the transaction, the director now directly owns 259,208 shares in the company, valued at $3,799,989.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Jinn Wu also recently made the following trade(s):
- On Friday, February 9th, Jinn Wu purchased 10,000 shares of Athenex stock. The stock was bought at an average price of $13.64 per share, for a total transaction of $136,400.00.
Shares of Athenex Inc (NASDAQ ATNX) traded down $0.88 during midday trading on Monday, reaching $15.32. 829,103 shares of the company’s stock were exchanged, compared to its average volume of 388,795. Athenex Inc has a one year low of $11.21 and a one year high of $20.79.
A number of brokerages have issued reports on ATNX. Zacks Investment Research downgraded shares of Athenex from a “buy” rating to a “hold” rating in a report on Thursday. Needham & Company LLC began coverage on shares of Athenex in a report on Tuesday, March 6th. They issued a “buy” rating and a $30.00 price target on the stock. BidaskClub upgraded shares of Athenex from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. JPMorgan Chase & Co. lifted their price target on shares of Athenex from $22.20 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 price target on shares of Athenex and gave the company a “buy” rating in a report on Wednesday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Athenex has an average rating of “Buy” and an average price target of $26.86.
COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3303250/athenex-inc-atnx-director-jinn-wu-buys-10000-shares.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.